Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Research

• Publication date

  2009-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-08-3708PMID 19244109PMCID PMC2683344
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of UGT1A and UGT2B mRNA in Human Normal Tissues and Various Cell Lines

  2008cited by this paper
• Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene

  2008cited by this paper
• Gene expression of 17beta-estradiol-metabolizing isozymes: comparison of normal human mammary gland to normal human liver and to cultured human breast adenocarcinoma cells.

  2008cited by this paper
• Glucuronidation of Active Tamoxifen Metabolites by the Human UDP Glucuronosyltransferases

  2007influential reference
• Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use.

  2007cited by this paper
• Elimination of Antiestrogenic Effects of Active Tamoxifen Metabolites by Glucuronidation

  2007cited by this paper
• Validation of Rapid Polymerase Chain Reaction-based Detection of All Length Polymorphisms in the UGT 1A1 Gene Promoter

  2007cited by this paper
• Molecular pathogenesis of Gilbert's syndrome: decreased TATA-binding protein binding affinity of UGT1A1 gene promoter

  2007cited by this paper
• IMPORTANCE OF UDP-GLUCURONOSYLTRANSFERASE 1A10 (UGT1A10) IN THE DETOXIFICATION OF POLYCYCLIC AROMATIC HYDROCARBONS: DECREASED GLUCURONIDATIVE ACTIVITY OF THE UGT1A10139LYS ISOFORM

  2006cited by this paper
• Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone.

  2006cited by this paper
• Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4.

  2006influential reference
• Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment

  2006cited by this paper
• Influence of Nonsynonymous Polymorphisms of UGT1A8 and UGT2B7 Metabolizing Enzymes on the Formation of Phenolic and Acyl Glucuronides of Mycophenolic Acid

  2006cited by this paper
• The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

  2006cited by this paper
• Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants

  2006influential reference
• Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

  2005influential reference
• Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

  2005cited by this paper
• Genotype–phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes

  2005cited by this paper
• Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen

  2005cited by this paper
• Correlation between the UDP-Glucuronosyltransferase (UGT1A1) TATAA Box Polymorphism and Carcinogen Detoxification Phenotype

  2004cited by this paper
• Correlation between UDP-Glucuronosyltransferase Genotypes and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone Glucuronidation Phenotype in Human Liver Microsomes

  2004influential reference
• Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen

  2004cited by this paper
• New approaches to the endocrine prevention and treatment of breast cancer

  2003cited by this paper
• Overview of the main outcomes in breast-cancer prevention trials.

  2003cited by this paper
• Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma risk

  2003cited by this paper
• [Tamoxifen and breast cancer].

  2002cited by this paper
• Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues.

  2002cited by this paper
• Effect of 4-hydroxytamoxifen isomers on growth and ultrastructural aspects of normal human breast epithelial (HBE) cells in culture.

  2002cited by this paper
• Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3.

  2002cited by this paper
• Relative Enzymatic Activity, Protein Stability, and Tissue Distribution of Human Steroid-Metabolizing UGT2B Subfamily Members**This work was supported by the Medical Research Council of Canada, the Fonds de la Recherche en Santé du Québec, and Endorecherche.

  2001cited by this paper
• Risk and Prognosis of Endometrial Cancer After Tamoxifen for Breast Cancer

  2001cited by this paper
• Homodimerization of Human Bilirubin-Uridine-diphosphoglucuronate Glucuronosyltransferase-1 (UGT1A1) and Its Functional Implications*

  2001cited by this paper
• Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members.

  2001cited by this paper
• Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.

  2000cited by this paper
• O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9.

  2000cited by this paper
• Risk and prognosis of endometrial cancer after tamoxifen for breast cancer

  2000cited by this paper
• Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus.

  1999cited by this paper
• Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

  1999cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Tamoxifen therapy for breast cancer and endometrial cancer risk.

  1999cited by this paper
• Tamoxifen and risk of idiopathic venous thromboembolism.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Tamoxifen in the treatment of breast cancer.

  1998cited by this paper
• Tamoxifen in the Treatment of Breast Cancer

  1998cited by this paper
• Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268).

  1998cited by this paper
• Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome

  1996cited by this paper
• The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome.

  1995cited by this paper
• Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group.

  1995cited by this paper
• Risk of endometrial cancer after tamoxifen treatment of breast cancer.

  1994cited by this paper
• Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994cited by this paper
• Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group.

  1993cited by this paper
• Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.

  1991cited by this paper
• [Tamoxifen and breast cancer].

  1991cited by this paper
• Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

  1989cited by this paper
• Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.

  1989cited by this paper
• Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile.

  1988cited by this paper
• Tamoxifen in the treatment of breast cancer.

  1988cited by this paper
• The pharmacology and clinical uses of tamoxifen.

  1984cited by this paper
• Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.

  1984cited by this paper
• Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen.

  1982cited by this paper
• A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.

  1977cited by this paper

• SULT and UGT Genetic Variants Modulate Side Effect Profiles in South African Breast Cancer Patients Treated with Tamoxifen

  2026cites this paper
• The impact of de novo lipogenesis on predicting survival and clinical therapy: an exploration based on a multigene prognostic model in hepatocellular carcinoma

  2025cites this paper
• Development and validation of a liquid chromatography-mass spectrometry assay for quantification of Z- and E- isomers of endoxifen and its metabolites in plasma from women with estrogen receptor positive breast cancer.

  2023cites this paper
• Impact of CYP2D6, CYP2C9/19, CYP3A4, UGT, and SULT Variability on Tamoxifen Metabolism in Breast Cancer Treatment

  2023cites this paper
• Cannabis Pharmacogenomics: A Path to Personalized Medicine

  2023cites this paper
• PGPM_A_308531 613..652

  2022cites this paper
• Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective

  2022cites this paper
• Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment

  2022cites this paper
• Effects of UGT2B7 rs7662029 and rs7439366 polymorphisms on sublingual buprenorphine metabolism in heroin addicts: an improved PCR-RFLP assay for the detection of rs7662029 polymorphism.

  2022cites this paper
• Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer

  2021cites this paper
• Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites

  2021cites this paper
• Pharmacogenomics and Morphine

  2021cites this paper
• Metabolic Pathway Analysis and Effectiveness of Tamoxifen in Danish Breast Cancer Patients

  2020cites this paper
• Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors

  2020cites this paper
• Bayesian Pathway Analysis for Complex Interactions.

  2020cites this paper
• Recent advances in the personalized treatment of estrogen receptor-positive breast cancer with tamoxifen: a focus on pharmacogenomics

  2020influential citation
• Practice of Epidemiology Bayesian Pathway Analysis for Complex Interactions

  2020cites this paper
• Non-CYP2D6 Variants Selected by a GWAS Improve the Prediction of Impaired Tamoxifen Metabolism in Patients with Breast Cancer

  2019cites this paper
• Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen

  2019influential citation
• Deep sequencing reveals the molecular pathology characteristics between primary uterine leiomyoma and pulmonary benign metastasizing leiomyoma

  2018cites this paper
• Osthole prevents tamoxifen-induced liver injury in mice

  2018cites this paper
• Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients

  2018cites this paper
• The outcomes of tamoxifen therapy in breast cancer patients and genotypes of SULT1A1 and glucuronosyltransferase

  2017cites this paper
• Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy.

  2017cites this paper
• UGT1A6- and UGT2B7-related valproic acid pharmacogenomics according to age groups and total drug concentration levels.

  2016cites this paper
• Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement.

  2016cites this paper
• Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients

  2016cites this paper
• Induction of UDP-Glucuronosyltransferase 2B15 Gene Expression by the Major Active Metabolites of Tamoxifen, 4-Hydroxytamoxifen and Endoxifen, in Breast Cancer Cells

  2015cites this paper
• Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients

  2015cites this paper
• Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer

  2015cites this paper
• Tamoxifen Pharmacokinetics Beyond the Genotyping Era

  2015cites this paper
• DMD058016 1392..1400

  2014cites this paper
• Influence of UGT2B7, OPRM1 and ABCB1 Gene Polymorphisms on Postoperative Morphine Consumption

  2014cites this paper
• UGT 2 B Gene Expression Analysis in Multiple Tobacco Carcinogen-Targeted Tissues s

  2014cites this paper
• Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.

  2014cites this paper
• UGT2B Gene Expression Analysis in Multiple Tobacco Carcinogen-Targeted Tissues

  2014cites this paper
• A Potential Role for Human UDP-Glucuronosyltransferase 1A4 Promoter Single Nucleotide Polymorphisms in the Pharmacogenomics of Tamoxifen and Its Derivatives

  2014cites this paper
• A potential role for human UDP‐glucuronosyltransferase 1A4 promoter SNPs in the pharmacogenomics of Tamoxifen and its derivatives (1141.13)

  2014cites this paper
• Pharmacogenomics–Pharmacoepigenomics of Breast Cancer Therapy: Clinical Implications

  2014cites this paper
• Characterization of Raloxifene Glucuronidation: Potential Role of UGT1A8 Genotype on Raloxifene Metabolism In Vivo

  2013cites this paper
• effects of CYP 2 D 6 and UGT 2 B 7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients

  2013influential citation
• Tamoxifen pharmacokinetics and pharmacogenetics in endocrine sensitive breast cancer patients

  2013cites this paper
• Lipid Metabolism Genes in Contralateral Unaffected Breast and Estrogen Receptor Status of Breast Cancer

  2013cites this paper
• Practical and clinical use of opioids

  2013cites this paper
• Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer

  2013cites this paper
• Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients

  2013influential citation
• In silico modeling of UDP-glucuronosyltransferase 1A10 substrates using the VolSurf approach.

  2012cites this paper
• Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid.

  2012cites this paper
• Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)7TAA and UGT1A4 L48V polymorphisms

  2012cites this paper
• Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer

  2012cites this paper
• Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance

  2012cites this paper
• High enzyme activity UGT1A1 or low activity UGT1A8 and UGT2B4 genotypes increase esophageal cancer risk.

  2012cites this paper
• Role of the Uridine Diphosphate Glucuronosyltransferase 2a Family in Tobacco Carcinogen Metabolism

  2012influential citation
• Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective

  2012cites this paper
• Su1843 High Enzyme Activity UGT1A1 or Low Activity Ugt1a8 and Ugt2b4 Genotypes Increase Esophageal Cancer Risk

  2012cites this paper
• Pharmacogenetics of Phase II Drug Metabolizing Enzymes

  2012cites this paper
• LC-MS in Drug Bioanalysis

  2012cites this paper
• Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes

  2011cites this paper
• UDP-glucuronosyltransferase 2B7 glucuronidation of the active tamoxifen metabolites

  2011influential citation
• Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants

  2011cites this paper
• Automation and Miniaturization of the Bioluminescent UGT-Glo Assay for Screening of UDP-Glucuronosyltransferase Inhibition by Various Compounds

  2011cites this paper
• Functional Polymorphisms in UDP-Glucuronosyl Transferases and Recurrence in Tamoxifen-Treated Breast Cancer Survivors

  2011influential citation
• Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer

  2011influential citation
• Characterization of UDP-glucuronosyltransferase 2A1 (UGT2A1) variants and their potential role in tobacco carcinogenesis

  2011cites this paper
• First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

  2011cites this paper
• Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors

  2010influential citation
• Genetic variations in UDP-glucuronosyltransferase 2B7 gene (UGT2B7) in a Korean population.

  2010cites this paper
• Herbal interactions with anticancer drugs: mechanistic and clinical considerations.

  2010cites this paper
• SNP Communication Genetic Variations in UDP-glucuronosyltransferase 2 B 7 Gene ( UGT 2 B 7 ) in a Korean Population

  2010cites this paper
• The role of UDP-glucuronosyltransferases and drug transporters in breast cancer drug resistance.

  2010cites this paper
• MECHANISMS OF VARIABILITY IN CYP2D6 METABOLISM: THE CONTRIBUTIONS OF POLYMORPHISMS, COPY NUMBER VARIATIONS AND microRNA

  2010influential citation
• Xenobiotic metabolism and zebrafish (danio rerio) larvae

  2010cites this paper
• Estimating the impact of molecular profiles and prescription drugs on breast cancer outcomes

  2010cites this paper
• Toxicology, Safety and Herb–drug Interactions in Cancer Therapy

  2010cites this paper
• Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.

  2010cites this paper
• Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectives.

  2010cites this paper
• Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics

  2010cites this paper
• Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review.

  2010cites this paper
• Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

  2010cites this paper
• Enzymatic Basis of Phase I and Phase II Drug Metabolism

  2010cites this paper
• Genetic polymorphism in metabolism and host defense enzymes: Implications for human health risk assessment

  2010cites this paper
• Basic science: (March 2009)

  2009cites this paper
• Is tamoxifen a genotoxic carcinogen in women?

  2009cites this paper
• Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.

  2009cites this paper
• CYP2D6 and tamoxifen: DNA matters in breast cancer

  2009cites this paper